Urologic Health Raises $11 Million Seed Funding for Non-Invasive Bladder Monitoring

Israel-based Urologic Health has announced the successful closing of an $11 million seed financing round led by an undisclosed strategic investor, with participation from Edge Medical Ventures, SHD Partners, Longevity Venture Partners, and additional healthcare-focused investors. The funding will support the company’s clinical validation, FDA 510(k) regulatory pathway, and initial U.S. commercialization efforts.
The company’s niu System is designed to deliver comprehensive bladder function data without catheterization, supporting routine, repeatable assessment and longitudinal monitoring of bladder function. Bladder dysfunction conditions, including overactive bladder, urinary retention, incontinence, and benign prostatic hyperplasia, affect hundreds of millions of people worldwide. Current diagnostic tools remain constrained by their invasiveness and discomfort, which often leads patients to defer or avoid necessary assessments.
Adam Yaacov, Co-founder and CEO of Urologic Health, stated that invasive urodynamics remains one of the most significant barriers in modern urological care. “While treatment options have evolved considerably, the invasive diagnostic process continues to present challenges for patients,” he said. “Urologic aims to make bladder function assessment easier for clinicians to perform, painless for patients to undergo, and more informative for longitudinal decision-making.”
Urologic Health has completed early feasibility studies demonstrating that the niu System can capture clinically meaningful bladder activity non-invasively. The company plans to use the new financing to advance clinical validation, continue product and manufacturing development, and establish its headquarters in Jersey City, New Jersey, in preparation for initial U.S. market entry.
Shai Policker, Managing Partner of Edge Medical Ventures and chairman of Urologic’s board, said the company was established through a venture creation model working with strategic industry partners to identify needs and bring together talented entrepreneurs. “By combining exceptional engineering talent in Israel with Edge’s operational support, we are able to help companies like Urologic Health move faster through clinical validation, regulatory execution, and early market entry in the United States,” he stated.
